Biogen’s $7.3B M&A deal, layoffs; R&D shakeup at Pfizer, AstraZeneca; Scaling rare disease meds; Q2 earnings; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The End­points news­room is con­tin­u­ing to grow! Rey­nald Cas­tañe­da joined us this week from Lon­don — he will lead two oth­er UK col­leagues, Ay­isha Shar­ma and An­na Brown, in beef­ing up our ear­ly morn­ing re­port­ing. On the US side, Ly­dia Ram­sey Pflanz­er will be spear­head­ing the ex­pan­sion of our cov­er­age in­to health tech. If you missed it, read Drew Arm­strong’s note for more.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN